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ABSTRACT  
To determine if mutations made to PLM could increase PLM-NKA binding we performed 
scanning mutagenesis of the transmembrane domain of PLM and measured FRET between each mutant 
and NKA. We observed increased binding to NKA for several PLM mutants compared to WT, including 
L27A, L30A, and I32A. In isolated cardiomyocytes, overexpression of WT PLM increased the amplitude 
of the Ca2+ transient compared to GFP control. Ca2+ transient amplitude was further increased by L30A 
PLM overexpression. L30A mutation also delayed Ca2+ extrusion and increased the duration of 
cardiomyocyte contraction. This mimics aspects of the effect of cardiac glycosides, which are known to 
increase contractility through inhibition of NKA. No significant differences between WT and L30A PLM 
expressing myocytes were observed after treatment with isoproterenol, suggesting that the superinhibitory 
effects of L30A are reversible with β-adrenergic stimulation. We also observed a decrease in PLM 
tetramerization with L30A compared to WT using FRET, suggesting that L30 is an important residue for 
mediating PLM-PLM binding. MD simulations revealed that the potential energy of the L30A tetramer is 
greater than the WT, and that the transmembrane alpha helix is distorted by the mutation. The results 
implicate PLM residue L30 as an important determinant of PLM tetramerization and of functional 
inhibition of NKA by PLM.  
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Heart failure, defined as insufficient cardiac output to meet the demands of the body 1, 2, is one of 
the leading causes of morbidity and mortality in the US3. Cardiac glycosides, such as digitalis, have been 
used to treat heart failure for centuries4-6. They act by selectively binding to the Na,K-ATPase (NKA) on 
the outside of cardiomyocytes, inhibiting pump activity7. This leads to an increase in cytosolic sodium 
concentration, [Na+]i, which in turn inhibits the Ca2+ extrusion activity of the sodium-calcium exchanger 
(NCX)8. Decreased Ca2+ extrusion prolongs the contraction and increases SR Ca2+ load, increasing 
contractility9. However, the therapeutic window of glycosides is narrow, as high doses lead to overload of 
Ca2+ in the SR, Ca2+ leak, and arrhythmogenesis5. In the event of an overdose, treatment with antibody to 
the drug is necessary, as drug clearance is otherwise relatively slow (the half-life of digoxin is 20-50 
hours, for example)6.  
NKA is also regulated by the endogenous peptide phospholemman (PLM, also referred to as 
FXYD1)10, 11, and in contrast to cardiac glycosides, this inhibition is dynamically regulated by the cell. 
PLM is phosphorylated on its C-terminus by PKA and PKC in response to adrenergic stimulation and this 
phosphorylation causes relief of inhibition of NKA (Fig. 1A)12. Phosphorylation may also modulate a 
parallel regulatory interaction of PLM with other Ca-handling proteins, such as NCX13-15. 
Phosphorylation has been shown to increase the formation of PLM tetramers (Fig. 1B), which are not 
believed to interact with NKA16-19. While monomeric PLM reduces the affinity of NKA for sodium ions, 
it has little to no effect on the maximum transport rate (Vmax) of NKA20. Therefore, inhibition by PLM can 
be overcome at high [Na+]i. For these reasons, we theorized that mutations made to PLM that increase 
binding to and inhibition of NKA (superinhibitory PLM) could be superior inotropic agents compared to 
cardiac glycosides.  
Whether PLM mutations could be positively inotropic (enhancing cardiac contractions) has not 
been extensively studied prior to the work in this publication. Here we sought to test the following 
hypothesis: a mutation made to the transmembrane domain of PLM will increase PLM-NKA binding, 
leading to downstream positive inotropy by inhibiting Na+ extrusion and consequently reducing Ca2+ 
efflux via NCX, mimicking the action of cardiac glycosides. Our approach was to use FRET to screen 19 
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PLM mutants and test candidates for functional effects in isolated cardiomyocytes. We also monitored the 
effect of mutation on PLM tetramerization to test whether oligomerization influences PLM-NKA binding.  
 
EXPERIMENTAL PROCEDURES 
Molecular biology and cell culture: PLM fused to Citrine (Cit) was previously described. This 
construct has PLM fused at the C-terminus to the N-terminus of the yellow fluorescent protein Cit with a 
21 residue linker12. Individual alanine substitutions were created by site-directed mutagenesis. 
Adenoviruses containing WT and mutant PLM-Cit DNA sequences were generated using the AdEasy kit 
(Stratagene) as previously described21. All DNA sequences were verified by sequencing (ACGT, Inc.). 
AAV-293 cells stably expressing enhanced cyan fluorescent protein (ECFP) tagged to the N-terminus of 
NKA22 were maintained in Dulbecco’s Modified Eagle’s medium (DMEM) + 10% FBS. Cells were 
transfected with 1 µg of PLM-Cit plasmid DNA per 60 mm dish of 250,000 cells (Turbofect, 
ThermoFisher) according to manufacturer instructions. 
Acceptor sensitization FRET and anisotropy measurements: 24 h post-transfection, cells were 
trypsinized and plated at a density of 150,000 cells/well in a 4-well glass-bottom chamber (MatTek). 
Cells were incubated for 90 min at 37°C in DMEM + 10% FBS, and then were washed two times with 
PBS, followed by loading with 2 µg/mL wheat germ agglutinin (WGA) Alexa Fluor 594 (Molecular 
Probes). WGA was applied to the cells for 3 min, then the cells were washed three times with PBS. 
Images of cells were acquired using a Nikon inverted microscope with 40X air objective. Acceptor 
sensitization FRET was used to measure binding between ECFP-NKA and each PLM-Cit construct. For 
each acquisition field, a set of four images was taken to capture the fluorescence of ECFP, Cit, FRET, and 
WGA Alexa Fluor 594, with exposure times of 2000, 50, 500, and 300 ms respectively. For the ECFP, 
Cit, and WGA images, the specific fluorophore was excited and its emission was captured, whereas for 
the FRET image, ECFP was excited and Cit emission was captured. Then the stage was automatically 
shifted so that a new field was in focus, and the imaging was repeated. For each PLM construct 130 fields 
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were imaged in rapid succession using automated stage movements. Focus on the cells was maintained 
using a Nikon PFS feedback system. 
To quantify PLM-PLM binding, the stage was reset back to the initial position, and image 
scanning was repeated, this time using polarization filters in order to measure fluorescence anisotropy of 
PLM-Cit. If the PLM-Cit peptides are in close proximity in the membrane, homotransfer FRET can occur 
between neighboring Cit fluorophores23. This energy transfer decreases the polarization of emitted 
fluorescence, which is quantified as a decrease in fluorescence anisotropy. To measure the anisotropy of 
PLM-Cit, vertically polarized excitation light (wavelength = 504/12 nm) was used and then emission was 
captured with either a vertical (Iparallel) or a horizontal (Iperpendicular) polarizing filter in the emission light 
path. Both of these images were acquired with an exposure time of 1000 ms. 
For each field the WGA Alexa Fluor 594 image, which displayed fluorescence only at the plasma 
membrane of each cell, was used to generate a “mask” that was then applied to all other images. This was 
done using a no-neighbors deconvolution algorithm (Metamorph) performed on the WGA images. Masks 
of just the plasma membrane of each cell were then applied to all the other images in order to reduce the 
contribution of any intracellular expression of fluorescent protein constructs. This allowed for the 
calculation of acceptor sensitization and anisotropy solely at the plasma membrane, where PLM-NKA 
and PLM-PLM binding is relevant. 
For each cell, acceptor sensitization FRET was calculated according to the formula: 
FRET Efficiency (%) = 100 * (IFRET – aICit – dIECFP) / (IFRET – aICit –dIECFP + GIECFP), 
where IFRET, ICit,, and IECFP are the average intensities of each cell in the FRET, Cit, and ECFP images, 
respectively, ‘a’ is the acceptor cross-excitation coefficient, ‘d’ is the donor bleed-through coefficient, and 
G is the ratio of sensitized emission to donor emission for a standard FRET construct (control donor-
acceptor fusion)24. For the experiments performed in this manuscript, a = 0.091, d = 0.83, and G = 4.6. 
Anisotropy was calculated according to the formula: 
r = (Iparallel - Iperpendicular) / (Iparallel + 2Iperpendicular),  
where r is the average anisotropy of each cell. 
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Calculation of PLM-PLM and PLM-NKA binding affinities: Average acceptor sensitization 
FRET and anisotropy values were plotted against the PLM-Cit fluorescence value of each cell (24). The 
data were fit by Hill functions in Origin software. Acceptor sensitization FRET was well described by the 
following relationship:  
FRET Efficiency (%) = c + ((FRETmax-c)*[Protein]n) / (KD2n + [Protein]n) 
where c is the FRET of the unbound fluorescent proteins, and FRETmax is the FRET of the fully bound 
regulatory complex; n is the Hill coefficient, and [Protein] is the average intensity of Cit for each cell in 
arbitrary units, taken to be an index of the concentration of PLM. KD2 is the dissociation constant for the 
PLM-NKA complex. Homotransfer FRET was evaluated by the following relationship:  
anisotropy (r) = r0 + ((rn-r0)*[Protein]n) / (KD1n + [Protein]n) 
where rn is the anisotropy of the fully bound PLM tetramer, and KD1 is the dissociation constant. The 
value r0 is the inherent anisotropy of unbound fluorescent proteins; however estimation of anisotropy for 
very dim (low expressing) cells was complicated by a variable background of highly polarized scattered 
light. Thus we do not consider values of r0 to be informative here. For each mutant PLM, four separate 
binding curves from four different transfections were globally fit, sharing all parameters except for KD. 
These four pairs of KD values were then averaged and plotted with associated SEM.  
Molecular Dynamics (MD) Simulations of WT and L30A PLM tetramers 
To compare the energetics of WT and L30A PLM oligomers we performed molecular dynamics 
simulations of a model of the PLM tetramer (Cluster 1)25 in GROMACS26, 27, using the CHARMM 36 28 
force field and TIP3P 29 water model. Energy minimization was performed on the PLM tetramers using 
the steepest descent method for 1000 steps, then the transmembrane helices of each model were inserted 
into a POPC lipid bilayer, removing overlapping lipids. The structure was solvated in a water box, with 
150 mM Na+ and Cl- ions added to neutralize the charge of the system. The Particle Mesh Ewald method 
30, 31 was used to calculate the long-range electrostatic interactions, with a cut-off of 12 Å for short-range 
interactions. Van der Waals interactions were reduced to zero by switch truncation applied from 8 to 12 
Å. To heat the system from 0 K to the target temperature (300 K) and reach the target pressure (1 bar), the 
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Berendesen method was used with relaxation times of 0.1 ps32. After 1 ns equilibration, the production 
run was performed in the NPT ensemble using the Nose-Hoover thermostat33, 34 and the Parrinello-
Rahman barostat 35, 36 with relaxation times of 1.0 ps. Three independent production runs were carried out 
for 50 ns for each variant with an integration time step of 2 fs. 
Physiological measurements in cardiomyocytes: Rabbit ventricular myocytes were isolated as 
previously described37. Cells were transferred to laminin-coated 14 mm cover slips (MatTek) and 
incubated for one hour in PC-1 medium (Lotran, Inc.). Virus was added to the cells at a multiplicity of 
infection of 500 virus particles per cell37. Cells were incubated and paced with 10V, 5 ms duration pulses, 
at a frequency of 0.1 Hz for 18 h. 
Cells were visualized using confocal microscopy in order to observe the expression and 
localization of the PLM-Cit. Cells were then washed twice with Tyrode solution and loaded with 10 µM 
Indo-1 acetoxymethyl ester for 20 min, followed by three more washes. Measurements were made with 
cells in the presence of either Tyrode solution alone, or 20 nM isoproterenol in Tyrode solution. Myocytes 
were stimulated using 30V, 2 ms duration pulses, and 0.5 Hz frequency37. Myocytes were measured only 
if they were contracting longitudinally, were properly adhered to the laminin-coated cover slip, and were 
not touching other cells. Using an IonOptix system, average sarcomere length and Indo-1 fluorescence 
were simultaneously measured. Ten pulses were measured for each cell. The resulting traces were then 
averaged together and fit using IonOptix software. 
Statistics: Data were plotted as mean ± SEM. Mutants were compared to WT using Student’s 
unpaired T-test, with significance being noted at p < 0.05.  
 
RESULTS 
 Effects of PLM mutations on PLM-PLM and PLM-NKA FRET: Transiently transfected HEK 
cells expressing fluorescently-tagged PLM mutants showed intracellular fluorescence near the nucleus 
(likely in the endoplasmic reticulum) and in the plasma membrane (Fig. 1C). To specifically quantify the 
fluorescence of PLM/NKA localized in the plasma membrane and exclude intracellular fluorescence, we 
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generated a selection mask from images of WGA labeled with Alexa Fluor 594 (Fig. 1C). We quantified 
PLM-NKA binding by measuring FRET between ECFP-NKA and each mutant PLM-Cit construct. The 
average FRET efficiency of each cell was compared to the intensity of Cit fluorescence, which was taken 
as an index of the expression of acceptor-labeled PLM. As previously observed18, FRET increased with 
PLM-Cit toward a maximum (Fig. 1D). The data are consistent with increased binding of PLM to NKA 
with increasing membrane protein concentration.  
PLM-PLM binding was quantified by homotransfer FRET measured from Cit fluorescence 
anisotropy. Cit has a high intrinsic fluorescence anisotropy and we observed decreasing anisotropy with 
increasing expression of PLM (Fig. 1E), consistent with increasing homotransfer FRET within the PLM 
tetramer. Acceptor sensitization/homotransfer FRET binding curves were analyzed by Hill function 
fitting, yielding the relative dissociation constants for the respective protein complexes: KD1 for the PLM 
tetramer, and KD2 for the PLM-NKA complex (Fig. 2). Fit results are provided in Table 1. A comparison 
of KD values of PLM mutants (Fig. 2) reveals differences from WT (indicated by *, p < 0.05). All PLM 
mutants showed robust homotransfer and acceptor sensitization FRET, indicating that all were capable of 
oligomerizing and binding to NKA (Table 1).  
As we previously observed12, 18, a phosphomimetic mutant of PLM with key phosphorylation sites 
S63 and S68 replaced with glutamate showed increased oligomerization compared to WT or a 
nonphosphorylatable (S63A/S68A) mutant of PLM. In that previous study, the increased oligomerization 
of S63E/S68E was matched by a decrease in binding to NKA (increased KD2)18. Here we also observed 
an increased KD2 relative to S63A/S68A (p < .0001) (though the value was not statistically 
distinguishable from WT, p = .067). The observed decrease in binding to NKA of the phosphomimetic 
mutant relative to nonphosphorylatable PLM confirms our previous conclusion that PLM phosphorylation 
reduces the apparent affinity of the interaction but does not abolish binding18.  The apparent persistence of 
the regulatory complex after phosphorylation is also consistent with a recent study by Mishra et al. in 
which they showed protection of NKA from heat denaturation by both WT and phosphomimetic PLM 38. 
Based on that apparent reciprocal relationship of KD1 and KD2 (increased oligomerization of S63E/S68E 
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matched by a decrease in binding to NKA)18 we previously hypothesized that oligomerization of PLM 
substantially limits the availability of the monomeric form. In a similar fashion, phospholamban (PLB) 
oligomerization is thought to determine its potency for regulating the sarco/endoplasmic reticulum 
calcium-ATPase (SERCA)39-41. However, in the present more extensive survey of PLM transmembrane 
domain mutations we did not observe a strong link between PLM oligomerization and PLM-NKA 
binding. In particular, many mutants showed enhanced NKA-binding despite apparently increased (or 
unaltered) oligomerization affinity. Mid-depth transmembrane domain alanine substitution mutants 
between I23A to S37A significantly increased binding to NKA, irrespective of their propensity for 
oligomerization. The data suggest that the relative availability of monomer is not the sole determinant of 
NKA-binding. One mutant that did conform to the expected inverse relationship of KD1 and KD2 was 
L30A PLM, which exhibited nearly 4-fold higher KD1 compared to WT and a ~2 fold lower KD2. It is not 
clear whether the increased binding to NKA is due soley to increased availability of monomer, or reflects 
increased intrinsic affinity of monomer for NKA. It may be that oligomerization and the NKA-PLM 
interaction are both independently affected by L30A. 
Effect of L30A mutation on PLM tetramer energetics: To identify possible structural 
mechanisms of depolymerization of PLM by L30A, we examined a model of the PLM tetramer generated 
in a previous study using site-specific infared spectroscopy and experimentally constrained high 
throughput MD simulations 16. Here we performed 50 ns MD simulations of model “Cluster 1”, which 
was selected from 6 alternative models on the basis of the relative orientation of protomers in the 
tetramer. In this model L30 protruded into the center of the tetramer, and we hypothesized that mutation 
of this residue could alter the stability of the complex. The quaternary arrangement of transmembrane 
helices is shown in Fig. 3A, viewed along the membrane normal axis from the cytoplasmic side, with the 
leu or ala at position 30 highlighted in blue. The relative positions of the transmembrane helices were 
stable over 50 ns for WT PLM, but we observed significant distortion of the L30A structure within the 
first few ns of the simulation (Fig. 3A), with some intrusion of lipid into the space created by the 
replacement of the bulky Leu sidechain with the smaller Ala. In addition, the consequence of loss of 
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contacts between the L30 sidechains and adjacent protomers was visible within the first 10 ns of the 
simulation as a difference in the potential energy between the WT (-2842 ± 172 kJ/mol) and mutant (-
2676 ± 174 kJ/mol).  This difference became more extreme over the course of the 50 ns trajectory. Fig. 
3B shows histograms of the binding energy values calculated at the beginning of the simulation (0-10 ns, 
thin lines) and the end of the simulation (40-50 ns, thick lines) for WT and L30A.  WT PLM became 
more stable over time, assuming a configuration with a more negative potential energy (-2970 ± 246 
kJ/mol) (Fig. 3B, thick black line).  In contrast, the evolution of the L30A mutant resulted in a less 
negative potential energy of the tetrtamer at the end of the simulation (-2536 ± 160 kJ/mol).  Overall, the 
less negative potential energy of the mutant relative to the WT, which worsened over time, suggested 
instability of the Cluster 1 tetramer structure after L30A mutation. The molecular dynamics simulations 
are compatible with the decrease in tetramer affinity (increase in KD1) observed for L30A PLM (Fig. 2A). 
We also examined an alternative model, "Cluster 6", which was previously identified as the structure in 
closest agreement with infrared spectroscopy measurements based on synthetic transmembrane peptides 
in dimyristoyl-phosphocholine lipids (31). A 10 ns simulation showed that compared to Cluster 1 the 
calculated potential energy of the WT Cluster 6 structure was somewhat less negative (-2753 ± 242 
kJ/mol).  Nevertheless, Cluster 6 potential energy was also increased by the L30A mutation (-2576 ± 212 
kJ/mol).  
Functional effects of PLM mutations: The physiological effect of NKA inhibition by cardiac 
glycosides is to increase intracellular Na+, resulting in decreased extrusion of Ca2+ by NCX and enhanced 
cardiac contraction42-45. We hypothesized that increased NKA binding by inhibitory PLM would have a 
similar effect. To evaluate this possible mechanism, we selected three candidate mutants (L27A, L30A 
and I32A) that showed increased apparent affinity for NKA (Fig. 2B). These PLM mutants were 
overexpressed in isolated rabbit ventricular myocytes using adenoviral delivery. After 24 h, confocal 
microscopy revealed that the PLM-Cit fluorescence was localized in the perinuclear region and in the 
plasma membrane (Fig. 4A). The plasma membrane fraction co-localized with Alexa Fluor 594 WGA in 
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a T-tubular pattern (Fig. 4A). Cells were electrically paced at 0.5 Hz to measure Ca2+ release (with Indo-
1) and cell shortening. Addition of exogenous WT PLM-Cit was associated with a prolongation of the 
Ca2+ transient (increased decay time constant t) and increased transient amplitude compared to non-fusion 
GFP controls (Fig. 4B). Importantly, this result suggests that not all pumps are bound or regulated by 
PLM in rabbit cardiomyocytes, and that physiological inhibition of NKA may be increased by delivery of 
PLM to the unoccupied regulatory sites. This is in contrast to observations of the related P-type ATPase, 
SERCA, which appears to be saturated by endogenous PLB in the rabbit heart.  A study of PLB-
overexpressing rabbits revealed no phenotype 46.   
To determine the effect of PLM mutations, we compared Ca2+ transients of cells expressing 
candidate mutants to cells expressing exogenous WT PLM-Cit. Relative to WT, L30A showed the most 
profound effect, prolonging the Ca2+ transient and modestly increasing Ca2+ transient amplitude (Fig. 4C, 
H). L27A and I32A effects were similar to WT (Fig. 4H-J). The effects of control GFP or PLM mutant 
overexpression on Ca2+ handling parameters are summarized in Fig. 4H-J, all normalized to WT. To 
determine whether cells expressing superinhibitory L30A PLM could respond to adrenergic stress we 
applied 20 nM isoproterenol and observed positive inotropy (enhanced contraction) and lusitropy 
(enhanced relaxation). After isoproterenol treatment L30A PLM-expressing cells showed no significant 
difference from cells expressing exogenous WT PLM (Fig. 4D,G). That we observed no residual 
broadening of the Ca2+ transient suggests that NKA superinhibition by L30A was relieved by activation of 
b-adrenergic pathways.  
Despite increased Ca2+ transient amplitude, we did not observe a significant increase in fractional 
shortening (Fig. 4E, F, K). However, we noted that the resting sarcomere length of the cultured 
cardiomyocytes was already quite short, possibly limiting further contraction. Instead, enhanced Ca2+ 
transients manifested as a longer contraction phase (Fig. 4E-F), as measured by a significantly larger full 
width at half maximum (FWHM) and increased relaxation time constant (Fig. 4L-M). The effects of 
control GFP or PLM mutant overexpression on cell shortening parameters are summarized in Fig. 4K-M, 
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all normalized to WT. The comprehensive results of the experiments comparing WT to L30A PLM under 
baseline conditions are summarized in Tables 2 and 3. 
 
DISCUSSION 
 There are several structure/function theories that have guided studies of PLM and related 
regulatory partners of transport ATPases. The first is that the oligomeric species of the regulatory peptide 
is a “storage” form that does not bind to the target ATPase. This model predicts that depolymerization of 
the oligomer would result in increased availability of the peptide for interaction with the ATPase 
enhancing the “apparent” affinity, reflected by a decrease Kd2. The analogous regulatory protein 
phospholamban mostly fulfills this prediction 39, 41, and our previous studies with PLM phosphorylation 
site mutants also suggested that oligomerization was a major determinant of NKA-binding 18. In that 
study we found that oligomerization and NKA-binding were inversely regulated by phosphorylation-
mimicking mutations at sites of PKA/PKC functional regulation.  Here we confirm that previous 
observation, compared to nonphosphorylatable mutant S63A/S68A the phosphomimetic mutant 
S63E/S68E shows increased oligomerization and a loss of NKA-binding (Fig. 2). However, our present 
more extensive survey of the PLM primary sequence also revealed several mutants that bind avidly to 
NKA yet are more oligomeric than WT (L33A, G31A, I26A, I23A) and a mutant that binds poorly to 
NKA but has an oligomerization dissociation constant that is the same as WT (I22A). Thus, we observed 
that the PLM mutants’ propensity for oligomerization was a very poor predictor of NKA binding.  
The second assumption tested here was that increased binding to NKA results in increased pump 
inhibition. Notably, many of the 19 PLM mutants tested here showed more avid NKA-binding than WT 
(Fig. 2B), suggesting that the NKA-PLM interaction has been tuned for less than maximal binding. The 
observed increase in apparent affinity recommends these mutants as possible superinhibitors of NKA.  
However, 2 of the 3 mutants selected for further study did not yield the expected physiological effect in 
isolated cardiomyocytes. Only one (L30A) showed signs of enhanced inotropic potency in cultured adult 
cardiac myocytes (Fig. 4). The apparent disconnect between binding and functional inhibition reminds us 
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of another group’s recent discovery of a small transmembrane peptide (DWORF) that appears to bind 
SERCA without inhibition 47. The data indicate that a gain of binding does not always yield a gain of 
inhibitory function. Likely the inverse is also true; perhaps some mutants that showed normal or 
decreased binding to NKA are still potent inhibitors of the pump. We conclude rationally designed 
modifications of regulatory proteins must be tested to verify that they have achieved the intended effect.  
The discovery of L30A as a gain-of-binding (Fig. 2B) and superinhibitory (Fig. 4) mutant may be 
a useful observation in the search for alternatives to conventional cardiac glycoside therapy. The 
enhanced Ca2+ handling and contractility are reminiscent of the action of clinically useful NKA inhibitors 
on isolated cardiomyocytes (45-48). Specifically, L30A PLM overexpression increased the amplitude of 
the Ca2+ transient and decay constant (Fig. 4C, H, J) and increased the duration of the contraction 
(FWHM) (Fig. 4F, L, M). The respective mechanisms of contractility modulation by cardiac glycosides 
and superinhibitory PLM are contrasted in Fig. 5. Cardiac glycosides inhibit a fraction of the NKA pumps 
(1).  With fewer active pumps, [Na+]i rises (2), inhibiting normal NCX extrusion of Ca2+ (3). In the 
context of heart failure, this accumulation of Ca2+ increases SR Ca2+ load and improves cardiac 
contractility. However, [Na+]i is already elevated in heart failure48, 49, and arrhythmias can be induced by 
excessive [Na+]i and by SR Ca2+ overload (4). Clinically, this is avoided by careful titration of the 
glycoside dose, but pharmacological NKA inhibition is not acutely regulated with responsiveness to 
stress. In contrast, the inhibition of NKA by PLM is dynamically regulated (Fig. 5B). Even superinhibiton 
by L30A PLM appeared to be reversed by phosphorylation, as we observed that Ca2+ handling and cell 
shortening transients of WT- and superinhibitory L30A-expressing cells converged after b-adrenergic 
stimulation. In addition, PLM decreases the activity of NKA by decreasing Na+ affinity (increasing KNa) 
while preserving Vmax20. Thus, a rise in [Na+]i is limited by reserve NKA activity.  
The present results provide insight into the importance of PLM transmembrane residues in 
determining PLM regulatory interactions with itself (oligomerization) and with NKA. Modification of 
these residues may tune the inhibitory potency of PLM by altering the amount of monomeric PLM 
available to interact with NKA (Fig. 2A), or by altering the intrinsic affinity of the monomer for the 
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regulatory target (Fig. 2B), or by changing the intrinsic inhibitory potency of PLM (Fig. 4). Finally, the 
results underscore the value of identifying superinhibitory variants of PLM that could be useful for 
increasing contractility while still retaining physiological reversibility during stress (Fig. 5B). 
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TABLES 
Table 1. Results of fitting acceptor sensitization FRET and anisotropy data with Hill functions. The 
fitting parameters for each PLM mutant are listed ± SEM. N ≥ 4 biological replicates. 
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Table 2. Ca2+ transient data for WT vs. L30A-expressing cells displayed as means ± SEM. p-values 
from Student's T-Test are listed. N = 4 biological replicates comprising a total of 38 myocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter WT L30A P-Value
Baseline Indo-1 0.444 0.431
Ratio ± 0.008 ± 0.003 0.139
Peak Indo-1 0.61 0.61
Ratio ± 0.01 ± 0.01 0.682
Transient 0.22 0.26
Amplitude ± 0.01 ± 0.01 0.036
Transient Amplitude 37 42
(% of Baseline) ± 2 ± 2 0.124
Departure Velocity 7.1 7.7
(sec.-1) ± 0.4 ± 0.4 0.331
Time to 10% 0.080 0.100
Peak (sec.) ± 0.008 ± 0.009 0.094
Time to 50% 0.037 0.040
Peak (sec.) ± 0.001 ± 0.002 0.231
Time to 90% 0.093 0.092
Peak (sec.) ± 0.005 ± 0.006 0.915
Time to Peak 0.20 0.23
(sec.) ± 0.01 ± 0.01 0.193
Return Velocity -0.30 -0.30
(sec.-1) ± 0.02 ± 0.02 0.940
Time to 10% 0.43 0.46
Baseline (sec.) ± 0.02 ± 0.03 0.387
Time to 50% 0.81 0.89
Baseline (sec.) ± 0.03 ± 0.03 0.053
Time to 90% 1.42 1.52
Baseline (sec.) ± 0.04 ± 0.02 0.027
Full Width at 0.77 0.85
Half Maximum (sec.) ± 0.03 ± 0.03 0.063
Ca2+ Decay Time 1.02 1.19
Constant (sec.) ± 0.07 ± 0.05 0.045
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Table 3. Myocyte contraction data for WT vs. L30A-expressing cells displayed as means ± SEM. p-
values from Student's T-Test are listed. N = 4 biological replicates comprising a total of 38 myocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter WT L30A P-Value
Baseline Sarcomere 1.714 1.675
Length (µm) ± 0.007 ± 0.006 <0.001
Length at Peak 1.584 1.559
Contraction (µm) ± 0.009 ± 0.006 0.023
Change in Length 0.130 0.116
(µm) ± 0.006 ± 0.005 0.086
Fractional Shortening 7.6 6.9
(%) ± 0.4 ± 0.3 0.148
Contraction Velocity -0.51 -0.37
(µm/sec.) ± 0.04 ± 0.03 0.007
Time to 10% 0.072 0.085
Peak (sec.) ± 0.004 ± 0.008 0.161
Time to 50% 0.201 0.233
Peak (sec.) ± 0.009 ± 0.009 0.013
Time to 90% 0.47 0.53
Peak (sec.) ± 0.02 ± 0.02 0.017
Time to Peak 0.68 0.81
(sec.) ± 0.03 ± 0.02 0.001
Relaxation Velocity 0.61 0.39
(µm/sec.) ± 0.08 ± 0.05 0.018
Time to 10% 0.84 1.02
Baseline (sec.) ± 0.03 ± 0.03 <0.001
Time to 50% 1.00 1.22
Baseline (sec.) ± 0.04 ± 0.03 <0.001
Time to 90% 1.22 1.45
Baseline (sec.) ± 0.05 ± 0.03 <0.001
Full Width at 0.80 0.99
Half Maximum (sec.) ± 0.04 ± 0.03 <0.001
Relaxation Time 0.40 0.56
Constant (sec.) ± 0.03 ± 0.04 0.002
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FIGURE LEGENDS 
Figure 1. Method for measuring PLM-PLM and PLM-NKA binding. (A) Primary amino acid 
sequences of the human and canine isoforms of PLM. The N-terminal residues (including the underlined 
FXYD motif) are extracellular and the C-terminal residues (including the phosphorylation sites, in boxes) 
are intracellular. The single transmembrane domain is highlighted in gray. For the current study the 
canine isoform was used. (B) PLM forms tetramers in the plasma membrane, and PLM monomer binds to 
and inhibits NKA. (C) HEK cells stably expressing ECFP-NKA (left), transiently transfected with PLM-
Cit (center), and stained with WGA Alexa Fluor 594 (right). (D) The average acceptor sensitization FRET 
efficiency of each cell co-transfected with ECFP-NKA and WT PLM-Cit, and (E) the average anisotropy 
of PLM-Cit are plotted against the intensity of Cit in arbitrary units (AU) as an index of [PLM]. Each 
point is derived from one cell. The data were fit with Hill functions shown in red. 
 
Figure 2. Effects of alanine substitution on PLM-PLM and PLM-NKA binding affinities. (A) For 
each PLM mutant, KD1 is plotted in arbitrary units (AU) ± SEM and compared to WT (dashed line). 
Mutants with KD1 less than the KD1 for WT are considered more oligomeric (greater PLM-PLM binding 
affinity) and mutants with a greater KD1 are considered less oligomeric. (B) KD2 is plotted in arbitrary 
units (AU) ± SEM for each mutant, and compared to WT (dashed line). Mutants with KD2 less than WT 
are considered gain-of-binding, and mutants with a greater KD2 are considered loss-of-binding. *p < 0.05 
compared to WT. 
 
Figure 3. Molecular dynamics simulations of WT and L30A tetramer structure models. (A) A 
comparison of the initial (start) and final (10 ns) tetramer structures, with the leu (WT) or ala (L30A) 
residues highlighted in blue. We observed significant distortion of the L30A tetramer during the 
simulation. (B) A histogram of potential energy values of structures sampled during the simulation 
reveals that the energy of the L30A PLM tetramer is increased compared to WT, suggesting decreased 
stability for the mutant structure. 
 
Figure 4. Functional effects of PLM mutants in myocytes. (A) A rabbit ventricular myocyte infected 
with adenovirus used to express PLM-Cit. The protein is synthesized in the SR and trafficked to the 
sarcolemma and T-tubules, as evidenced by co-localization with WGA Alexa Fluor 594. (B) Averaged 
Ca2+ transients for myocytes overexpressing WT PLM (black) and GFP (red) are plotted as the 
normalized fluorescence ratio of Indo-1 over time, ±SEM. (C) Ca2+ transients for WT (black) vs. L30A 
PLM (red). (D) Same as C, but in the presence of 20 nM isoproterenol. (E) The myocyte contractions 
corresponding to the experiment in B. (F) Myocyte contractions corresponding to the experiment in C. 
(G) The myocyte contractions corresponding to the experiment in D. Values in E-G are mean ±SEM. (H) 
Averaged Ca2+ transient amplitude. (I) Ca2+ transient full width at half maximum. (J) Ca2+ decay time 
constant. (K) Fractional shortening. (L) Full width at half maximum for cell contractions. (M) Cell 
relaxation time constant. Values in H-M are mean ± SEM, normalized to WT, * indicates p < 0.05 
compared to WT.  
 
Figure 5. Pharmacological vs. physiological inhibition of NKA. (A) Cardiac glycosides act by binding 
to and inhibiting the activity of NKA in the sarcolemma of cardiomyocytes (1). This leads to an increase 
in [Na+]i, which inhibits the ability of NCX to extrude calcium (2). As calcium rises in the cytosol and in 
the SR (3), contractility is increased as intended. However, overdose of cardiac glycosides leads to 
overload of calcium in the SR and leakage out of the SR, potentially causing an arrhythmia (4). (B) In this 
study, L30A PLM displayed increased binding to NKA (compared to WT PLM), and mimicked the 
effects of cardiac glycosides on isolated cardiomyocytes. Following β-adrenergic stimulation, which is 
known to cause PLM phosphorylation, there were no differences between WT- and L30A-overexpressing 
cells, suggesting that the effect of L30A mutation was physiologically reversible.  
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